mynth
← DATABASE
03/2021

COOPER-VEMEDIA acquired by CVC

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs EV €1–10bn

Context

CVC acquired a majority stake in Cooper-Vemedia from Charterhouse. The transaction, valued at EUR2.2 billion, was won in a competitive process against a PAI/Ontario Teachers' consortium. The acquisition reflects CVC's appetite for high-cash-flow businesses with low capital intensity (Capex ~EUR10M). The goal is to pursue a buy-and-build strategy across Europe.

COOPER-VEMEDIA, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a level close to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A leading European consumer healthcare platform specialized in over-the-counter (OTC) treatments. Its portfolio includes iconic brands such as Oenobiol, Audispray, Mercurochrome, and Dakin. The group operates as both a manufacturer and a powerful distributor with a massive pharmacy network.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
€450–900M
€100–200M
[members only]
2019
€450–900M
€100–200M
[members only]

Similar deals in Life Sciences

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
DateAcquirerTargetCountrySector
04/2021NESTLETHE BOUNTIFUL COMPANYUNITED STATESNutrition & Dietary Supplements
04/2021NAXICAP PARTNERSLAGARRIGUEFRANCEImplants & Prosthetics
02/2021SIPAREXWINNCAREFRANCEMedical Devices
02/2021IK PARTNERSInnovad GroupBELGIUMAnimal Health
01/2021MONTAGU PRIVATE EQUITYIMV TECHNOLOGIESFRANCER&D Biotech
01/2021ARDIAN / BNP PARIBAS DEVELOPPEMENTPROTEORFRANCEImplants & Prosthetics
01/2021SAGARDNUTRISENSFRANCENutrition & Dietary Supplements
11/2020NOVALPINA CAPITALLABORATOIRE X.OFRANCEGenerics / Labs
10/2020ARDIANH2 PHARMAFRANCECDMO
10/2020SULZERHASELMEIERSWITZERLANDMedical Consumables

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €450–900M

EBITDA range: €100–200M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of COOPER-VEMEDIA by CVC are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: cvc